Lung Cancer Clinical Trials: 3376 Active Trials, 454 Changes This Month

Also in this update: Completion moved earlier from Feb 28, 2029 to Nov 12, 2027; Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026

AstraZenecaPhase 3 NCT05984277 Registry history of NCT05984277 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

Calderasib (MK-1084) and Durvalumab · Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Trial sites expanded: 91 → 95 locations

And 4 more changes in the last 30 days

Merck Sharp & Dohme LLCPhase 3 NCT07554339 Registry history of NCT07554339 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer

Enrollment closed, study ongoing

Also in this update: Completion moved earlier from Jul 30, 2027 to Dec 30, 2026; Primary completion moved earlier from Jun 30, 2027 to Nov 30, 2026

The Hong Kong Polytechnic UniversityNot applicable NCT07281300 Registry history of NCT07281300 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Minor

ECLAIR · Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer

Enrollment closed, study ongoing

Also in this update: Primary completion pushed from Aug 1, 2026 to Nov 1, 2026

Universitaire Ziekenhuizen KU LeuvenNot applicable NCT07259447 Registry history of NCT07259447 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026

Minor

Setidegrasib (ASP3082) With Docetaxel, · Non-small Cell Lung Cancer With a KRAS G12D Mutation

Trial sites expanded: 17 → 22 locations

And 1 more change in the last 30 days

Astellas Pharma Global Development, Inc.Phase 3 NCT07566052 Registry history of NCT07566052 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Minor

Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

Primary completion pushed from Aug 2026 to Dec 2026

Stanford UniversityPhase 3 NCT04585490 Registry history of NCT04585490 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy · Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Trial sites expanded: 479 → 484 locations

And 1 more change in the last 30 days

PfizerPhase 3 NCT07222566 Registry history of NCT07222566 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Minor

Platform Study of Select Immunotherapy Combinations · Advanced Non-small Cell Lung Cancer (NSCLC)

Trial sites reduced: 56 → 52 locations

Servier Bio-Innovation LLCPhase 1/2 NCT06162572 Registry history of NCT06162572 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

CLARITY · Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Primary completion pushed from Sep 2026 to Dec 2026

Abramson Cancer Center at Penn MedicineNot specified NCT04305613 Registry history of NCT04305613 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026

Minor

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy · Transformed Small Cell Lung Cancer

Trial sites expanded: 57 → 61 locations

And 1 more change in the last 30 days

PfizerPhase 2 NCT07476287 Registry history of NCT07476287 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

SOHO-02 · How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, · Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Enrollment increased: 444 → 555 participants

BayerPhase 3 NCT06452277 Registry history of NCT06452277 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

Krascendo 2 · Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin · Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Trial sites expanded: 280 → 288 locations

Hoffmann-La RochePhase 3 NCT06793215 Registry history of NCT06793215 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Minor

Selpercatinib (LY3527723) · Rearranged During Transfection (RET)-Altered Cancers in India

Trial sites expanded: 3 → 10 locations

And 1 more change in the last 30 days

Eli Lilly and CompanyPhase 4 NCT07822880 Registry history of NCT07822880 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Minor

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Trial sites expanded: 90 → 104 locations

And 4 more changes in the last 30 days

PfizerPhase 1/2 NCT07227298 Registry history of NCT07227298 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Minor

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Trial sites expanded: 29 → 37 locations

And 1 more change in the last 30 days

PfizerPhase 2 NCT07489066 Registry history of NCT07489066 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026

Minor

Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Primary and study completion pushed from Dec 18, 2026 to May 15, 2027

Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

LUNAR-2 · TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Trial sites expanded: 98 → 104 locations

NovoCure GmbHPhase 3 NCT06216301 Registry history of NCT06216301 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Minor

GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy · Advanced or Metastatic Solid Tumors

Enrollment increased: 76 → 102 participants

GI Innovation, Inc.Phase 1/2 NCT07172802 Registry history of NCT07172802 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Minor

RAINFOL-05 · Rina-S · Non-small Cell Lung Cancer

Trial sites expanded: 74 → 91 locations

GenmabPhase 2 NCT07288177 Registry history of NCT07288177 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Minor

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment · Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Trial sites expanded: 386 → 413 locations

SWOG Cancer Research NetworkPhase 2/3 NCT06616584 Registry history of NCT06616584 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

DK222 Study at Hopkins

Primary and study completion pushed from Sep 1, 2027 to Jan 31, 2028

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT07140315 Registry history of NCT07140315 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Primary completion pushed from Oct 2026 to Dec 2026

Case Comprehensive Cancer CenterPhase 2 NCT07104630 Registry history of NCT07104630 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026

Minor

CPI · Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy

Primary and study completion pushed from Dec 2028 to May 2029

Centre Antoine LacassagnePhase 4 NCT07633613 Registry history of NCT07633613 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026

Minor

TeLuRide-008 · EIK1001 in Combination With Pembrolizumab and Chemotherapy · Stage 4 Non-Small Cell Lung Cancer

Trial sites expanded: 24 → 28 locations

Eikon TherapeuticsPhase 2/3 NCT07365319 Registry history of NCT07365319 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells · Mesothelin-Expressing Solid Tumors Including Mesothelioma

Enrollment increased: 100 → 120 participants

National Cancer Institute (NCI)Phase 1 NCT06885697 Registry history of NCT06885697 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Calderasib (MK-1084) and Other Treatments · Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Trial sites expanded: 215 → 218 locations

And 2 more changes in the last 30 days

Merck Sharp & Dohme LLCPhase 3 NCT07190248 Registry history of NCT07190248 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026

Minor

OP-3136 in Advanced or Metastatic Solid Tumors

Trial sites expanded: 8 → 25 locations

Olema Pharmaceuticals, Inc.Phase 1 NCT06784193 Registry history of NCT06784193 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026

Minor

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Trial sites expanded: 266 → 278 locations

SWOG Cancer Research NetworkPhase 2 NCT06031688 Registry history of NCT06031688 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

KANDLELIT-013 · MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Trial sites expanded: 106 → 110 locations

And 2 more changes in the last 30 days

Merck Sharp & Dohme LLCPhase 3 NCT07431827 Registry history of NCT07431827 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026

Minor

FOCUS-01 · AVA6103 · Locally Advanced or Metastatic Selected Solid Tumors

Trial sites expanded: 3 → 7 locations

Avacta Life Sciences LtdPhase 1 NCT07454642 Registry history of NCT07454642 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026

Minor

LARCS · Lung cAncer Robotic Comparative Study

Enrollment increased: 512 → 600 participants

Intuitive SurgicalNot specified NCT06038227 Registry history of NCT06038227 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026

Minor

Pumitamig Versus Pembrolizumab · Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Trial sites expanded: 279 → 284 locations

Bristol-Myers SquibbPhase 3 NCT07361510 Registry history of NCT07361510 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

HER3-DXd · Locally Advanced or Metastatic Solid Tumors

Trial sites expanded: 91 → 94 locations

Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026

Minor

RASolve 301 · Daraxonrasib (RMC-6236) · RAS Mutated NSCLC (RASolve 301)

Trial sites expanded: 153 → 158 locations

Revolution Medicines, Inc.Phase 3 NCT06881784 Registry history of NCT06881784 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

CONNECT · Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

Primary and study completion pushed from Sep 30, 2026 to Dec 30, 2026

Wake Forest University Health SciencesNot applicable NCT06383988 Registry history of NCT06383988 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

Social Optimization Study

Primary and study completion pushed from Jul 31, 2026 to Oct 31, 2026

University of ArizonaNot applicable NCT07564960 Registry history of NCT07564960 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

Called PF-08046054/SGN-PDL1V Versus Docetaxel · Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Trial sites expanded: 431 → 449 locations

PfizerPhase 3 NCT07144280 Registry history of NCT07144280 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026

Minor

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works · Non-small Cell Lung Cancer With High Levels of PD-L1

Trial sites expanded: 372 → 389 locations

PfizerPhase 3 NCT06758401 Registry history of NCT06758401 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Trial sites expanded: 295 → 300 locations

AstraZenecaPhase 3 NCT06627647 Registry history of NCT06627647 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Trial sites expanded: 262 → 365 locations

BioNTech SEPhase 2/3 NCT06712316 Registry history of NCT06712316 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026

Minor

Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care · Relapsed/Refractory Small Cell Lung Cancer

Trial sites expanded: 65 → 71 locations

AbbViePhase 3 NCT07365241 Registry history of NCT07365241 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Trial sites expanded: 325 → 328 locations

AstraZenecaPhase 3 NCT06692738 Registry history of NCT06692738 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026

Minor

HARMONi-7 · Ivonescimab for First-line Treatment of Metastatic NSCLC · High PD-L1

Trial sites expanded: 274 → 285 locations

Summit TherapeuticsPhase 3 NCT06767514 Registry history of NCT06767514 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026

Minor

DeLLphi-315 · Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

Trial sites expanded: 2 → 9 locations

AmgenPhase 3 NCT07778316 Registry history of NCT07778316 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Minor

Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care · Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Trial sites expanded: 110 → 116 locations

AbbViePhase 2/3 NCT07155187 Registry history of NCT07155187 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026

Minor

DESTINY-Lung06 · Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Trial sites expanded: 237 → 242 locations

Daiichi SankyoPhase 3 NCT06899126 Registry history of NCT06899126 on ClinicalTrials.gov (opens the registry)

Updated Sep 15, 2026

Minor

RELATIVITY1093 · Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Trial sites expanded: 322 → 326 locations

Bristol-Myers SquibbPhase 3 NCT06561386 Registry history of NCT06561386 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026

Minor

Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy · Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Trial sites expanded: 414 → 418 locations

AmgenPhase 3 NCT05920356 Registry history of NCT05920356 on ClinicalTrials.gov (opens the registry)

Updated Sep 11, 2026

Minor

ALX2004 With Advanced or Metastatic Selected Solid Tumors

Trial sites expanded: 8 → 12 locations

ALX Oncology Inc.Phase 1 NCT07085091 Registry history of NCT07085091 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

NT-175 · Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Trial sites reduced: 23 → 20 locations

AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

AmiNA · Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy · Resectable EGFR-Mutated NSCLC

Trial sites expanded: 20 → 23 locations

Janssen Research & Development, LLCPhase 2 NCT07586202 Registry history of NCT07586202 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Trial sites expanded: 3 → 16 locations

Blueprint Medicines CorporationPhase 1/2 NCT07629960 Registry history of NCT07629960 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

YL201 in Combination With Other Anti-Cancer Therapies · Advanced Solid Tumors

Trial sites expanded: 22 → 38 locations

MediLink Therapeutics (Suzhou) Co., Ltd.Phase 1/2 NCT07407933 Registry history of NCT07407933 on ClinicalTrials.gov (opens the registry)

Updated Sep 17, 2026

Minor

THIO Sequenced With Cemiplimab in Advanced NSCLC

Trial sites expanded: 35 → 40 locations

Maia BiotechnologyPhase 2 NCT05208944 Registry history of NCT05208944 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026

Minor

NAPISTAR1-01 · FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 · PROC or r/r Adenocarcinoma NSCLC

Trial sites expanded: 18 → 29 locations

Gilead SciencesPhase 1/2 NCT06303505 Registry history of NCT06303505 on ClinicalTrials.gov (opens the registry)

Updated Sep 11, 2026

Minor

Called Ponsegromab · Lung Cancer-Associated Significant Body Weight Loss

Trial sites expanded: 0 → 7 locations

PfizerPhase 1 NCT07663630 Registry history of NCT07663630 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Trial sites expanded: 17 → 20 locations

IDEAYA BiosciencesPhase 1 NCT07277413 Registry history of NCT07277413 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026

Minor

BL-M14D1 · Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Trial sites expanded: 20 → 24 locations

SystImmune Inc.Phase 1 NCT07080242 Registry history of NCT07080242 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026

Minor

MK-2870-001 · I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Completion pushed from Dec 31, 2026 to Nov 30, 2027

Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025

Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026

Minor

Pan-tumor MRD Study

Trial sites expanded: 2 → 47 locations

Paradigm HealthNot specified NCT06605404 Registry history of NCT06605404 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026

Minor

External Control Arm Study in Non-Small Cell Lung Cancer

Trial sites expanded: 8 → 11 locations

N-Power MedicineNot specified NCT07174388 Registry history of NCT07174388 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026

Minor

Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) · Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Primary and study completion moved earlier from Apr 27, 2029 to Feb 15, 2029

Merck Sharp & Dohme LLCPhase 1/2 NCT06780137 Registry history of NCT06780137 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Minor

BREATHE · Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

Trial sites expanded: 1 → 4 locations

Nantes University HospitalNot applicable NCT06481813 Registry history of NCT06481813 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026

Minor

Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions modified

Also in this update: Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026; and 1 more change in the last 30 days

Bristol-Myers SquibbPhase 2 NCT07680764 Registry history of NCT07680764 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability

Trial sites expanded: 18 → 23 locations

Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

DAREON ® -Lung-1: A Study · Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Start date moved earlier from Apr 13, 2026 to Nov 7, 2025

Boehringer IngelheimPhase 3 NCT07472517 Registry history of NCT07472517 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Trial sites expanded: 8 → 11 locations

H. Lee Moffitt Cancer Center and Research InstitutePhase 2 NCT06745882 Registry history of NCT06745882 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Trial sites expanded: 27 → 49 locations

Institut de Recherches Internationales ServierPhase 1/2 NCT05786924 Registry history of NCT05786924 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026

Minor

Mevrometostat · Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Interventions modified

PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Obrixtamig in Combination With Pumitamig · Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

Start date pushed from Sep 24, 2026 to Oct 5, 2026

Boehringer IngelheimPhase 1/2 NCT07843940 Registry history of NCT07843940 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

STELLAR-002 · Zanzalintinib in Combination With Immuno-Oncology or Other Agents · Solid Tumors

Interventions modified

ExelixisPhase 1 NCT05176483 Registry history of NCT05176483 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026

Minor

DAREON®-36 · Obrixtamig in Combination With ZL-1310 · Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Start date pushed from Sep 29, 2026 to Oct 19, 2026

Boehringer IngelheimPhase 1/2 NCT07707895 Registry history of NCT07707895 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

GSK5764227 · Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

Interventions modified

GlaxoSmithKlinePhase 3 NCT07099898 Registry history of NCT07099898 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

TROPION-Lung12 · Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, · Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Completion moved earlier from Jun 30, 2027 to Mar 31, 2027

Also in this update: Primary completion date changed from estimate of Jun 30, 2027 to Jul 10, 2026

AstraZenecaPhase 3 NCT06564844 Registry history of NCT06564844 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

MARIPOSA-2 · Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy · Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Completion pushed from Nov 30, 2027 to Jul 3, 2028

Janssen Research & Development, LLCPhase 3 NCT04988295 Registry history of NCT04988295 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy · Extensive-Stage Small Cell Lung Cancer (TIGOS)

Interventions modified

Bristol-Myers SquibbPhase 3 NCT06646276 Registry history of NCT06646276 on ClinicalTrials.gov (opens the registry)

Updated Sep 11, 2026

Minor

How BI 765063 and BI 770371 Are Taken up in Tumours · Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Completion moved earlier from Jul 14, 2027 to Nov 25, 2026

Boehringer IngelheimPhase 1 NCT05068102 Registry history of NCT05068102 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Minor

Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking Cessation in Heavy Smokers

Interventions modified

Hôpital Cantonal de FribourgNot applicable NCT07860359 Registry history of NCT07860359 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026

Minor

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Completion pushed from Mar 31, 2027 to Sep 30, 2027

Janssen Research & Development, LLCPhase 2 NCT05663866 Registry history of NCT05663866 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

BNT327, an Investigational Therapy · Small-cell Lung Cancer in Combination With Chemotherapy

Completion moved earlier from May 2028 to Feb 2028

BioNTech SEPhase 2 NCT06449209 Registry history of NCT06449209 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026

Minor

JNJ-86974680 · Advanced Non-small Cell Lung Cancer

Completion moved earlier from Jun 7, 2029 to Nov 30, 2027

Johnson & Johnson Enterprise Innovation Inc.Phase 1 NCT06116786 Registry history of NCT06116786 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

CHRYSALIS · Amivantamab, a Human Bispecific EGFR and cMet Antibody, · Advanced Non-Small Cell Lung Cancer

Completion pushed from Dec 31, 2026 to Dec 31, 2027

Janssen Research & Development, LLCPhase 1 NCT02609776 Registry history of NCT02609776 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Minor

[68Ga]Ga-DWJ155 · Solid Tumors

Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026

Novartis PharmaceuticalsPhase 1 NCT07801508 Registry history of NCT07801508 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026

Minor

Pembro and Vorinostat · Stage IV Non-small Cell Lung Cancer (NSCLC)

Completion pushed from Jul 2026 to Jun 2027

H. Lee Moffitt Cancer Center and Research InstitutePhase 1/2 NCT02638090 Registry history of NCT02638090 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026

Minor

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy · Cancer

Completion pushed from Sep 1, 2026 to Feb 1, 2027

SWOG Cancer Research NetworkNot specified NCT03939481 Registry history of NCT03939481 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics · Resectable NSCLC

Interventions modified

Also in this update: Primary completion date changed from estimate of Sep 2027 to Dec 31, 2024

Xiangya Hospital of Central South UniversityPhase 2 NCT04699721 Registry history of NCT04699721 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Adding Certolizumab to Chemotherapy + Nivolumab · Lung Cancer That Can Be Treated With Surgery

Interventions modified

Memorial Sloan Kettering Cancer CenterPhase 2 NCT04991025 Registry history of NCT04991025 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026

Minor

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Primary completion date changed from estimate of Jan 2027 to Sep 23, 2026

University of Colorado, DenverPhase 1/2 NCT05845671 Registry history of NCT05845671 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026

Minor

Genetic Testing in Screening · Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Completion pushed from Sep 28, 2026 to Sep 21, 2027

Also in this update: Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025; Final enrollment: 7458 participants (planned 8300)

National Cancer Institute (NCI)Not applicable NCT02194738 Registry history of NCT02194738 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

DoceRamPem · DoceRamPem · Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Primary completion date changed from estimate of Sep 2, 2026 to Apr 30, 2026

Emory UniversityPhase 2 NCT04340882 Registry history of NCT04340882 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026

Minor

Personalized Cancer Vaccine (PCV) Strategy · Solid Tumors and Molecular Residual Disease

Interventions modified

Washington University School of MedicinePhase 1 NCT06529822 Registry history of NCT06529822 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026

Minor

SPARC · Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier

Start date pushed from Sep 1, 2026 to Sep 8, 2026

University of UtahNot specified NCT07460440 Registry history of NCT07460440 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026

Minor

32 trials marked Unknown by the registry's verification sweep

Minor

TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3 NCT06469879 Registry history of NCT06469879 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

SHR-A2102 in Combination With Adebrelimab and SHR-8068 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 1/2 NCT06589778 Registry history of NCT06589778 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors

Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Recruiting

Chongqing Precision Biotech Co., LtdPhase 1 NCT06010862 Registry history of NCT06010862 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

NI-1801 · Mesothelin Expressing Solid Cancers

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Light Chain Bioscience - Novimmune SAPhase 1 NCT05403554 Registry history of NCT05403554 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting

Ningbo Medical Center Lihuili HospitalNot applicable NCT06188650 Registry history of NCT06188650 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Registry marked status Unknown (sponsor has not verified the record since Sep 2023); last known: Not Yet Recruiting

Degan LuPhase 3 NCT06048315 Registry history of NCT06048315 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Hunan Province Tumor HospitalPhase 2 NCT06537297 Registry history of NCT06537297 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Intrathecal Pemetrexed for SCLC · Refractory Brain Metastases or Leptomeninges Metastatic

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Hunan Province Tumor HospitalPhase 2 NCT06497543 Registry history of NCT06497543 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

High-dose Furmonertinib in the Treatment · Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Recruiting

Changhai HospitalPhase 2 NCT06394674 Registry history of NCT06394674 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

NТО-RAS · Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory · RAS Mutations

Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting

N.N. Petrov National Medical Research Center of OncologyPhase 2 NCT06229340 Registry history of NCT06229340 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC

Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting

Nanfang Hospital, Southern Medical UniversityPhase 2 NCT06177925 Registry history of NCT06177925 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalPhase 2 NCT05379803 Registry history of NCT05379803 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy · Resectable Stage II-IIIB

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalPhase 2 NCT05295212 Registry history of NCT05295212 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

JS-201 Combined With Lenvatinib · Small-cell Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalPhase 2 NCT04951947 Registry history of NCT04951947 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

CAPSTONE · Camrelizumab Plus Famitinib as Treatment · Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Qian ChuPhase 2 NCT04888429 Registry history of NCT04888429 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

BTVA in COPD and Ablation in Pulmonary Nodules by Pulmonary MRI

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Shanghai Chest HospitalNot specified NCT07045532 Registry history of NCT07045532 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Immunotherapy, the Occurrence and Severity of Adverse Reactions · Non-small Cell Lung Cancer in High-altitude Areas

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Second Affiliated Hospital of Xi'an Jiaotong UniversityNot specified NCT06757114 Registry history of NCT06757114 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNot specified NCT06653478 Registry history of NCT06653478 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Advance Care Planning Impact on the Consistency · Lung Cancer and Their Potential Surrogates Regarding Life-Sustaining Treatment Preferences

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting

National Taiwan University HospitalNot applicable NCT06616909 Registry history of NCT06616909 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Ruijin HospitalNot specified NCT06608160 Registry history of NCT06608160 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Xuanwu Hospital, BeijingNot applicable NCT06607926 Registry history of NCT06607926 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Mobile Application on Enhancing Pulmonary Rehabilitation After Lung Cancer Surgery

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

National Cheng Kung UniversityNot applicable NCT06600503 Registry history of NCT06600503 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Immuno-effect of Tα1 for Stage I NSCLC

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Yousheng MaoNot applicable NCT06598839 Registry history of NCT06598839 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Shanghai Pulmonary Hospital, Shanghai, ChinaNot specified NCT06592430 Registry history of NCT06592430 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting

Shanghai East HospitalNot specified NCT06586801 Registry history of NCT06586801 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalNot specified NCT06183762 Registry history of NCT06183762 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Double-dose Furmonertinib · Slow Osimertinib-resistant NSCLC

Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNot specified NCT06117644 Registry history of NCT06117644 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

SkinHealth · Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT05878964 Registry history of NCT05878964 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Nov 2023); last known: Recruiting

Ruijin HospitalNot applicable NCT05557552 Registry history of NCT05557552 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Yongchang ZhangNot specified NCT04777175 Registry history of NCT04777175 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalNot specified NCT04324125 Registry history of NCT04324125 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026
Minor

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting

Hunan Province Tumor HospitalNot specified NCT04324151 Registry history of NCT04324151 on ClinicalTrials.gov (opens the registry)

Changed Oct 4, 2026

Registry verification sweep

Changed Oct 4, 2026

Minor

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing · CEA Positive Cancer

Completion pushed from Aug 11, 2026 to Jul 14, 2027

City of Hope Medical CenterNot applicable NCT02293954 Registry history of NCT02293954 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026

Minor

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Primary completion date changed from estimate of Mar 2027 to Jul 2, 2026

H. Lee Moffitt Cancer Center and Research InstituteNot applicable NCT06337552 Registry history of NCT06337552 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026

Minor

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

Completion pushed from Jun 15, 2026 to Oct 1, 2026

City of Hope Medical CenterNot applicable NCT04905082 Registry history of NCT04905082 on ClinicalTrials.gov (opens the registry)

Updated Sep 11, 2026

First posted	Trial	Sponsor	Phase
2026-10-08	NCT07864584 Study Using a Drug-device Combination Product to Determine Safety, Tolerability and…	Nob Hill Therapeutics, Inc. new	Phase 1/2
2026-10-07	NCT07864207 Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With…	IDP Discovery Pharma S.L. new	Phase 1/2
2026-10-06	NCT07860359 Impact of Lung Cancer Screening With Chest Scans Combined With Coaching on Smoking…	Hôpital Cantonal de Fribourg new
2026-10-06	NCT07861282 Impact of a Telerehabilitation-based Therapeutic Exercise Program on Postoperative…	University of Seville new
2026-10-05	NCT07857694 Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma	Laibin People's Hospital new
2026-10-05	NCT07858253 CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy	Anusha Chidharla, MD new	Phase 2
2026-10-01	NCT07853443 Symptoms, Physical Function, and Recovery in Patients Receiving Lung Cancer Treatment…	Aerospace Center Hospital new
2026-10-01	NCT07853157 AI-Assisted 3D Reconstruction for Lung Resection Planning	S. Andrea Hospital new
2026-09-30	NCT07849400 Video-guided Versus Conventional Right-sided Double-lumen Tube Placement for…	Diansan Su new
2026-09-29	NCT07847138 The Effect of Music on Anxiety and Caregiver Burden in Family Caregivers of Patients With…	Izmir Bakircay University new

NCT ID	Title	Sponsor	Status	Updated
Phase 4
NCT03340506	Dabrafenib and/or Trametinib Rollover Study	Novartis Pharmaceuticals	Recruiting	2026-10-09
NCT07761351	A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing…	Intuitive Surgical	Recruiting	2026-09-25
NCT07279935	Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After…	AstraZeneca	Recruiting	2026-08-27
NCT06908070	Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab	Idris Bahce	Recruiting	2026-08-20
NCT07704658	Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors	Rigel Pharmaceuticals	Recruiting	2026-08-10
NCT07754812	Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment…	Shanghai Pulmonary Hospital, Shanghai, China	Recruiting	2026-08-10
NCT07744698	Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer…	Anhui Provincial Cancer Hospital	Recruiting	2026-08-04
NCT07405086	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or…	OHSU Knight Cancer Institute	Recruiting	2026-06-12
NCT06646471	PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With…	GFPC Investigation	Recruiting	2026-04-29
NCT06330038	Anesthesia and Non-small Cell Lung Cancer Recurrence	Samsung Medical Center	Recruiting	2026-04-20
NCT05521789	Erector Spinae Block for Thoracic Surgery	George Washington University	Recruiting	2026-02-25
NCT06105801	EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation…	Vanderbilt-Ingram Cancer Center	Recruiting	2026-02-02
NCT07320105	Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy…	Fujian Cancer Hospital	Recruiting	2026-01-06
NCT05463913	Lung Nodule Detection Using Ultra-long FOV PET/CT	University Medical Center Groningen	Recruiting	2025-03-07
NCT06467786	Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer	Tang-Du Hospital	Recruiting	2024-06-21
NCT05525338	Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib…	University Medical Center Groningen	Recruiting	2024-05-13
NCT05663242	The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and…	Kaohsiung Medical University Chung-Ho Memorial Hospital	Recruiting	2023-05-30
NCT05172739	Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in…	University of Crete	Recruiting	2021-12-29
NCT07822880	A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection…	Eli Lilly and Company	Not Yet Recruiting	2026-10-08
NCT05874401	Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)…	Pharmacosmos A/S	Active, Not Recruiting	2026-10-05
NCT05144997	Lorlatinib Continuation Study	Pfizer	Active, Not Recruiting	2026-09-23
NCT07633613	Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor…	Centre Antoine Lacassagne	Not Yet Recruiting	2026-09-15
NCT07802847	Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and…	Gustave Roussy, Cancer Campus, Grand Paris	Not Yet Recruiting	2026-09-03
NCT07768358	Tucatinib Continuation Study	Pfizer	Not Yet Recruiting	2026-08-28
NCT07674368	Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed	Hunan Cancer Hospital	Not Yet Recruiting	2026-07-01

Early Phase 1		36
Phase 1		421
Phase 1/2		326
Phase 2		838
Phase 2/3		50
Phase 3		336
Phase 4		35

Lung Cancer clinical trials

What changed in the last 30 days